When Should You Stop Taking Wegovy — and How Do You Know?

NICE sets a clear 6-month checkpoint: if you haven't lost at least 5% of your starting body weight after six months at the maintenance dose, continuing treatment is unlikely to be the right course and should be reviewed.
Weight regain is common after stopping: clinical evidence shows most people regain a significant proportion of lost weight without continued treatment or sustained lifestyle support, something to plan for, not be surprised by.
Pregnancy, breastfeeding, or trying to conceive: Wegovy is not recommended in any of these situations; stopping should be discussed with your prescriber well in advance.
Serious side effects that don't settle: symptoms such as severe, persistent abdominal pain, signs of an allergic reaction, or significant gallbladder trouble require prompt medical review and may mean stopping immediately.

Stopping Wegovy is a clinical decision, not a calendar one. The right time depends on how much weight you've lost, whether you're still responding to treatment, your wider health picture, and what your prescriber finds on review. There is no universal cut-off date, but there are recognised signals that a prescriber uses to guide that conversation. Because semaglutide is a prescription-only medicine, the decision to stop, pause, or continue always sits with the clinician who assessed you — not a timetable or a target number on the scales. The sections below walk through the main scenarios, in roughly the order they arise in practice.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The main reasons to stop Wegovy, and how each one plays out

Step 1, The 6-month progress check: what the guidance actually says

NICE's appraisal of semaglutide for weight management (TA875) is explicit: if someone hasn't achieved at least 5% body-weight reduction after six months on the maintenance dose, the clinical case for continuing is weak. That threshold isn't punitive, it reflects the evidence that people who respond to semaglutide tend to do so within that window. People who don't cross it are unlikely to see meaningful further loss.

In practice, this check should already be built into your treatment. At nume, at nume, every repeat order goes through a clinical re-review. A named prescriber looks at your progress before authorising more treatment, which means the 6-month question surfaces naturally rather than being left to you to raise. If the numbers aren't there, your prescriber will discuss what comes next: whether that's a different approach, a change in lifestyle support, or another option altogether.

It's also worth knowing that NICE recommends semaglutide is used for a maximum of two years within the NHS specialist pathway. Private prescribing sits outside that specific framework, but the underlying clinical logic (treatment as a tool with a defined purpose, not an open-ended prescription) applies regardless of route.

Step 2, Side effects serious enough to stop for

Most people on Wegovy experience some gut-related effects: nausea, loose stools, reflux, or occasional vomiting, especially after starting or after a dose step. These are typically mild to moderate and settle within a week or two. They're rarely a reason to stop, and working through them steadily, at the prescriber's pace, is part of how the treatment is designed to be taken.

What does warrant stopping, or at least urgent medical review, is a different pattern. Severe, persistent abdominal pain that radiates toward the back (with or without vomiting) can be a sign of acute pancreatitis. The MHRA highlighted this risk in a Drug Safety Update in January 2026, noting pancreatitis as a known but infrequent side effect that can be serious. Gallbladder problems, significant allergic reactions, and mood changes including low mood or thoughts of self-harm are also reasons to contact a clinician promptly rather than waiting for your next scheduled review.

If you're unsure whether what you're experiencing is a normal adjustment or something more, the Patient Information Leaflet that comes with your pen is the first place to check, and our support team is available seven days a week.

Step 3, Life circumstances that change the picture

Some stopping points aren't about efficacy or side effects. Pregnancy is the clearest: Wegovy isn't recommended during pregnancy, whilst breastfeeding, or when actively trying to conceive. If any of those situations apply (or are on the horizon) the conversation with your prescriber needs to happen before the situation arises, not after. There's a wash-out period to factor in, and that needs planning time.

Surgery is another trigger. Telling your anaesthetist and surgical team that you're taking a GLP-1 medicine before any procedure is essential; they'll advise on when to pause. Equally, if you've reached a stable weight and want to explore whether stopping Wegovy is the right call for you, that's a legitimate reason to have the conversation, though your prescriber should be part of that decision. The evidence on what happens when people stop Wegovy is covered in detail on a separate page about what to expect after stopping, and it's worth reading before you make the call.

One practical note: some people find they keep going past a sensible review point simply because repeat orders feel automatic. Payday, a Monday order, a holiday, it's easy to reorder without stepping back. A structured re-review, like the one built into every nume order, stops that drift happening.

When stopping isn't the same as finishing

Stopping Wegovy doesn't have to mean the end of support. If you've done well on treatment and are thinking about how long you should stay on Wegovy, the answer depends on your goals, your health history, and how your weight responds once the medicine is removed. Some people step down to a lower maintenance dose rather than stopping outright; others move to a different approach, and our guidance on how to stop taking Wegovy safely walks through what that process looks like in practice. None of this should be decided in isolation.

The fuller clinical picture (including how long Wegovy typically takes to produce results and what that trajectory looks like) is set out on our Wegovy treatment page. If you're weighing up when the right time to stop taking Wegovy might be and you'd like a prescriber's view on your specific situation, a free consultation with our clinical team is the most direct way to get one.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions